

**Supplementary Table 5. Inflammatory marker values across cancer types.** Unadjusted mortality, median inflammatory marker values with interquartile ranges, and categorically distributed inflammatory marker values shown for primary tumor site categories of the whole dataset ( $n=1,071$ ).

Tumor Site	Unadjusted Mortality	NLR (median, IQR)	PLR (median, IQR)	OIS (median, IQR)	mGPS (0/1/2, %)	PI (0/1/2, %)
Head & Neck	38.2%	7.1 (10.8)	390.4 (245.0)	39.8 (9.2)	5/6/11 (22.7%/27.3%/50.0%)	5/21/3 (17.2%/72.4%/10.3%)
Lung & Thoracic	47.4%	7.8 (9.4)	296.3 (249.3)	37.8 (9.7)	21/23/38 (25.6%/28.0%/46.3%)	13/86/26 (10.4%/68.8%/20.8%)
Gastroesophageal	32.7%	8.2 (12.5)	238.0 (415.4)	38.4 (10.6)	8/5/18 (25.8%/16.1%/58.1%)	7/19/10 (19.4%/52.8%/27.8%)
Hepatobiliary	47.3%	6.4 (8.3)	212.5 (265.6)	33.8 (10.8)	13/5/18 (36.1%/13.9%/50.0%)	12/25/10 (25.5%/53.2%/21.3%)
Duodenal & Lower GI Tract	38.6%	6.3 (9.2)	309.7 (221.3)	36.5 (10.5)	18/16/42 (23.7%/21.1%/55.3%)	16/62/13 (17.6%/68.1%/14.3%)
Breast	20.9%	4.3 (5.9)	221.7 (202.3)	39.8 (8.4)	36/37/33 (34.0%/34.9%/31.1%)	33/89/14 (24.3%/65.4%/10.3%)
Gynecological	36.8%	4.9 (5.9)	282.6 (273.6)	36.7 (10.3)	5/9/24 (13.2%/23.7%/63.2%)	5/35/8 (10.4%/72.9%/16.7%)
Genitourinary	34.3%	6.6 (10.7)	271.9 (266.0)	38.0 (8.7)	26/51/78 (16.8%/32.9%/50.3%)	18/123/29 (10.6%/72.4%/17.1%)
Skin	39.5%	6.1 (9.0)	217.5 (276.6)	42.5 (15.0)	3/20/11 (8.8%/58.8%/32.4%)	1/26/8 (2.9%/74.3%/22.9%)
Lymphoma	33.3%	4.8 (5.8)	214.8 (335.5)	40.0 (11.1)	22/14/21 (38.6%/24.6%/36.8%)	20/32/8 (33.3%/53.3%/13.3%)
Other	26.6%	5.6 (9.4)	255.5 (284.9)	39.1 (10.6)	12/10/13 (34.3%/28.6%/37.1%)	12/28/11 (23.5%/54.9%/21.6%)

NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; OIS: OnCovid Inflammatory Score; mGPS: Modified Glasgow prognostic score; PI: Prognostic index; IQR: Interquartile range; GI: Gastrointestinal